News

Both invasive aspergillosis and mucormycosis are life-threatening fungal infections predominantly occurring in immunocompromised patients. In March 2015, the US Food and Drug Administration (FDA) approved a new drug

Motolimod is a new Toll-like Receptor 8 (TLR8) agonist that directly activates multiple components of the innate immune system, which includes human myeloid dendritic cells (mDCs), monocytes and

The company is seeking US marketing approval of MM-398 to treat patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. Earlier, Merrimack

Additionally, the CHMP has recommended approval of Lixiana to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) as well as to prevent recurrent DVT and PE in

As part of the deal, Celgene will make an upfront payment of $100m in cash and an additional $385m in contingent payments upon research, development and regulatory advances.

The alliance is expected to boost the global medical writing capabilities of Synchrogenix. CISCRP has been working on this initiative for four years. The initiative will enable the

The report highlights that a once-daily combination of grazoprevir/elbasvir cured 95% of both the HCV infected, treatment-naive (C-EDGE TN), and HIV/HCV co-infected, treatment-naive (C-EDGE CO-INFXN) patients after 12

FSHD is a severe, rare genetic myopathy with an immune component for which there are currently no approved treatments. Being developed as an intravenous protein therapeutic for the

DCR-PH1 is the company’s proprietary DsiRNA-EX-based therapeutic candidate being developed for the treatment of PH1, which often results in kidney failure, and for which there are no approved